Truvestments Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$269K |
| 2 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$197K |
| 3 |
Altria Group
MO
|
+$144K |
| 4 |
MPT
Medical Properties Trust
MPT
|
+$127K |
| 5 |
ExxonMobil
XOM
|
+$117K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$582K |
| 2 |
Marathon Petroleum
MPC
|
+$200K |
| 3 |
AerCap
AER
|
+$196K |
| 4 |
XPO
XPO
|
+$195K |
| 5 |
Campbell Soup
CPB
|
+$186K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.31% |
| 2 | Healthcare | 10.05% |
| 3 | Consumer Staples | 8.95% |
| 4 | Communication Services | 7.78% |
| 5 | Industrials | 7.57% |
Similar funds
Truvestments Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Truvestments Capital held 704 positions worth $144M, down 6% from $154M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Truvestments Capital withdrew a net $18.1M in Q4 2019, closing 564 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $582K position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Staples.
Against the trend, Truvestments Capital opened a new position in Vanguard FTSE Developed Markets ETF worth $204K.
- Truvestments Capital's largest Q4 2019 buy was Vanguard FTSE Developed Markets ETF: 4,627 shares worth $204K.
- Truvestments Capital added most to Bristol-Myers Squibb in Q4 2019, an estimated $269K increase.
- Truvestments Capital's biggest Q4 2019 reduction was Apple, cutting an estimated $151K.
- Truvestments Capital fully exited Celgene Corp in Q4 2019, selling an estimated $582K.
- Truvestments Capital's ten largest holdings make up 27% of its $144M portfolio in Q4 2019.
- Truvestments Capital opened 1 new position and closed 564 in Q4 2019.
- Truvestments Capital's portfolio value fell 6% quarter-over-quarter to $144M.
Based on Truvestments Capital's 13F filing for Q4 2019, filed 29 Jan 2020.